Intuitive Investment Decision

Keineui · 2026-07-15T11:04:01.773446Z

After @jkb92 @Raketentoni convinced me to add this intuitive new stock to my portfolio. Edit: Unfortunately, the link to JKB isn't working for some reason.

Raketentoni@Raketentoni

3Mes

Well, I didn't say you should buy it 😬 I just posted my analysis 🙃

•

12

•

jkb92@jkb92

3Mes

@Raketentoni It's important to clarify 😁

•

3

•

Luke@Klassi

3Mes

@Raketentoni Where can I find this analysis? I couldn't find it on your profile :)

••

Brian@Aktienhauptmeister

3Mes

I'll be posting more in the coming days 🤝

•

3

•

jkb92@jkb92

3Mes

@Aktienhauptmeister What does the Moat Reaper say?

•

1

•

Brian@Aktienhauptmeister

3Mes

@jkb92 Jack on the Mic. jkb92, you asked about me?

🏰 1. The Business & The Moat
The moat: Extremely high. Due to the intensive training surgeons receive on the da Vinci system and the millions invested by hospitals, the switching costs are enormous.
The Model: A perfect “razor-and-blade” principle. The installed base ensures recurring, high-margin revenue through consumables and service subscriptions.
The Driver: The ramp-up cycle of the new da Vinci 5 (D5) further drives technological market leadership.

🧬 2. The Financial DNA Check
The Strengths: Outstanding profitability (real FCF margin of 21.8%, non-GAAP operating margin at 36%) paired with an absolutely crisis-proof, debt-free balance sheet (over $8 billion in net cash).

The “Weaknesses”: Increased Capex (8.2% of revenue) and longer inventory turnover periods. However, this is healthy growth capital, as ISRG is rapidly expanding its manufacturing facilities to meet the enormous demand for the D5.

📐 3. The Valuation Turnaround
Misjudgment corrected: A price of ~$650 would have been completely overheated (16.5% required annual FCF growth).

Fair reality: At the current price of ~€335 (~$380), the stock commands a historically fair implied FCF growth rate of ~10.5% per year over a 10-year horizon. For such a high-quality giant, this is an absolutely realistic, almost conservative hurdle. The stock is therefore in the buy range.

📅 4. Earnings Prep (Q2 2026 – tomorrow evening, July 16)
The consensus: Revenue of ~$2.82 billion (+15.7% YoY) and non-GAAP EPS of ~$2.41–$2.51 are expected.

What matters:
1. Will procedure growth once again post a strong beat (over 15–16%)?

2. Will D5 ramp-up costs weigh on the gross margin (guidance is 67.5% to 68.5%)?

3. Will the China business stabilize?

🎯 5. The Reaper Ruling & Action Plan

Tomorrow evening, there are three possible outcomes. Here’s how to react based on your trading setup:

🟢 Scenario 1: A Smooth Victory (Beat & Raise)
Numbers: Revenue > $2.85 billion, EPS > $2.55, procedure growth > 16%.
Reaction: The stock will surge in after-hours trading. No FOMO (Fear of Missing Out)! Since we’ve rated the stock at €335 as “fairly valued” but not “severely undervalued,” we won’t chase the price. We’re staying put.

🟡 Scenario 2: The “In-Line” Quarter (Numbers OK, Outlook Cautious)
Numbers: Revenue hits the mark (~$2.82 billion), procedures stable at 14–15%.
Reaction: The market may react with slight disappointment, as ISRG has historically always had a significant “beat” priced in. This is our observation zone. If the stock price dips slightly, we’ll be approaching the entry range.

🔴 Scenario 3: The Setback (Miss or Margin Pressure Due to D5 Costs)
Numbers: Gross margin slips below 67%, procedure growth weakens toward 13%.

Reaction: The Reaper’s hour. In the event of a major sell-off (toward €310), our bargain-hunting limit kicks in. This is exactly why you’ve built up your cash position.

Jack’s takeaway for tomorrow:
Let the Wall Street speculators squirm tomorrow. If the numbers are spectacular, we’ll welcome the fundamental confirmation but won’t chase the stock at high prices. If the market acts up and punishes the stock without causing structural damage, we’ll lie in wait.
ISRG has slipped straight from the “Completely Overpriced” tier into the “Affordable Quality Zone.” Anyone looking to get in for the long term no longer has to wait for a gigantic bubble to burst.

RATING: ~$380 ACCEPTABLE (First tranche absolutely justifiable)
BARGAIN HUNTER LIMIT: €310.00 (~$350) for aggressive follow-on buying
REAPER SCORE: 8.5 / 10

•

4

•

jkb92@jkb92

3Mes

@Aktienhauptmeister Thanks. How long have you been here?

••

Brian@Aktienhauptmeister

3Mes

@jkb92 I opened a position a few months ago, so I'm currently down about 15% 🤷🏼‍♂️

•

2

•

jkb92@jkb92

3Mes

@Aktienhauptmeister Oh, that's convenient—either way, you'll lower your cost of goods sold :)

•

1

•

Brian@Aktienhauptmeister

3Mes

@Keineui So, 350 USD is getting closer and closer 😏

•

3

•

jkb92@jkb92

3Mes

@Aktienhauptmeister Are you in? The $350 seems to be holding up, at least so far.

••

Brian@Aktienhauptmeister

3Mes

@jkb92 Yep, I've upped my order.

•

2

•

jkb92@jkb92

3Mes

Wow, now let's wait and see if we'll be happy or annoyed tomorrow after the numbers come out—since we've only placed the first tranche so far 😁

•

1

•

jkb92@jkb92

3Mes

@jkb92 In my estimation, the downside potential is limited to about 12%. According to Gemini, the options market is pricing in a 7% move in either direction.

••

Max@Maximilian1

3Mes

I think that was a mistake

•

1

•

jkb92@jkb92

3Mes

@Divident_e 😁 You already commented on that in his other post (“falling knife”). If you’re really interested in the topic, feel free to elaborate on your assessment :)

•

1

•

jkb92@jkb92

4G

@Maximilian1 Do you still feel that way? :)

•

1

•

jkb92@jkb92

3Mes

Heute: https://goldesel.de/aktien/news/intuitive-surgical-ubs-stuft-isrg-auf-buy-hoch-und-nennt-kursziel-von-500-usd